NH001 – Coma recovery
NH001 promotes consciousness and improves the functional outcome in patients in a post-traumatic coma, vegetative state or minimally conscious state. The faster the patient recovers consciousness, the better the chances for recovery of functionality.

As a result of trauma, portions of the brain die. During the recovery process, the remaining functional structures of the brain reorganize and take control of functions formerly controlled by the now dead structures. This natural healing is mediated by a process that is referred to as neural plasticity. NH001 aims to provide the right conditions in order to accelerate the neural plasticity process.

NeuroHealing has designed two clinical trials to study the safety and efficacy of NH001 in accelerating the recovery and improving the functional outcome of post TBI vegetative state and minimally conscious state patients. The first clinical trial is a small open label, Phase II study that has begun enrolments at two sites, with a dramatic response in the first four patients treated. NeuroHealing has recently received clearance by the FDA to start a Phase II, 76-patient, double blind, placebo controlled trial. Targeting a US market potential of $1 billion in peak revenues, NH001 is ready to enter Phase II clinical trials in 2008 with results available 18 months later, reaching the market in 2012.
- Get the NH001 Program Summary

NH004 – Sialorrhea
NeuroHealing is developing a novel treatment for sialorrhea (drooling or un-controlled salivation), the major non-motor complaint of Parkinson's Disease patients and often described as the a major debilitating social problem in many neurological conditions including Cerebral Palsy and ALS. Current treatments, which include surgery, Botox injections and oral anticholinergic drugs, are unsatisfactory. NeuroHealing's approach is based on a novel formulation of a safer anticholinergic compound that down-regulates secretory glands. NH004 has already shown activity in clinical tests. It has a favorable safety profile, a rapid onset and duration of action best to manage the problem, and a convenient product form for use on an "as needed" basis for sialorrhea control.
- Get the NH004 Program Summary

NH02D – Post-stroke, post-TBI motor recovery
Traumatic brain injury (TBI) and stroke victims often require years of rehabilitation and many never recover full functionality. NeuroHealing believes that the use of drug therapy can expedite and improve the rehabilitation of physical and cognitive functionality in TBI and stroke survivors. NeuroHealing has conducted a small open label clinical study of NH002, a drug with a well documented safety profile, with patients who have lost arm functionality as a result of a TBI or a stroke. Based on these findings NH02D, an improved formulation designed for this patient population, is in development.